Alnylam Delivers In-Line Numbers
Alnylam Pharmaceuticals Inc.’s (NASDAQ:ALNY) fourth quarter 2011 loss of 33 cents per share was in line with the Zacks Consensus Estimate. The loss was however wider than the year-ago loss of 16 cents per share. Lower revenues and higher general and administrative (G&A) expenses led to widening losses. Revenues for the reported quarter fell 3.3% [...]
Alnylam Pharmaceuticals Inc.’s (NASDAQ:ALNY) fourth quarter 2011 loss of 33 cents per share was in line with the Zacks Consensus Estimate. The loss was however wider than the year-ago loss of 16 cents per share. Lower revenues and higher general and administrative (G&A) expenses led to widening losses.
Revenues for the reported quarter fell 3.3% from the prior year to $20.5 million. Revenues were almost in line with the Zacks Consensus Estimate of $21 million.
In 2011, Alnylam reported total … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards